HLA-B27 Syndromes

IWBCA
Feb 17
6 min read

HLA-B27 is a specific allele of the HLA-B gene that encodes a class I human leukocyte antigen on nucleated cells, where it presents intracellular peptide fragments to cytotoxic T lymphocytes and shapes immune recognition of viral, microbial, and self-derived peptides, thereby influencing susceptibility to immune-mediated disease. It is an inherited marker whose frequency varies across populations and is strongly associated with several spondyloarthritides, including ankylosing spondylitis, reactive arthritis, and selected forms of psoriatic and inflammatory bowel disease–associated arthritis. The presence of HLA-B27 alone does not establish a diagnosis, but in an appropriate clinical context it substantially increases disease risk, which is why HLA-B27 testing is used as a supportive diagnostic tool alongside symptoms, examination, and imaging instead of as a general screening test.

Overview

What diseases and syndromes are associated with the HLA-B27 antigen?

HLA-B27 is one of the strongest genetic risk markers identified in immune-mediated disease. In ankylosing spondylitis, HLA-B27 positivity increases the relative risk several dozen-fold compared with HLA-B27–negative individuals, even though only a minority of carriers ever develop the condition. This allele defines a family of HLA-B27–associated spondyloarthritides that includes ankylosing spondylitis, reactive arthritis, selected forms of psoriatic arthritis, and inflammatory bowel disease–associated spondyloarthritis. Although HLA-B27 is present in a relatively small share of the general population, it is highly enriched in specific clinical environments. In acute anterior uveitis clinics, for example, roughly half of patients test positive, which illustrates how strongly HLA-B27 shapes patterns of joint and eye inflammation in those settings.

Across these conditions, HLA-B27–associated disease emerges where genetic predisposition intersects with dysregulated immune responses. The allele does not generate inflammation in isolation. It modifies how the immune system handles peptide fragments from both host tissues and microbes, lowers the threshold for T-cell activation, and promotes inflammatory signaling in certain contexts. This altered recognition and response pattern makes it easier for some carriers to develop persistent inflammation in the spine, sacroiliac joints, peripheral joints, entheses, intestines, and ocular tissues.

Major Histocompatibility Complex (MHC) and HLA-B27

The HLA system is encoded within the major histocompatibility complex, a cluster of genes that helps the immune system distinguish self from non-self. Class I molecules, such as HLA-A, HLA-B, and HLA-C, are present on nearly all nucleated cells and present small peptide fragments to CD8 T lymphocytes, which can eliminate infected or abnormal cells. Class II molecules, including HLA-DR, HLA-DQ, and HLA-DP, are expressed mainly on professional antigen-presenting cells such as macrophages, dendritic cells, and B cells and present peptides to CD4 T lymphocytes that coordinate broader immune responses. Class III genes encode other immune components, including complement proteins and cytokines. Across classes I and II, the core function is the same. These molecules bind peptide fragments and display them on the cell surface for inspection by T-cell receptors, thereby shaping how the adaptive immune system responds to pathogens and altered self.

Within this framework, HLA-B27 is a class I molecule that strongly influences CD8 T-cell responses to particular peptide sets. Its unique biochemical and structural features appear to alter how peptides are processed and presented, which helps explain its distinctive association with spondyloarthritis and related ocular and intestinal inflammation.

How HLA-B27 Alters Immune Signaling

The precise way in which HLA-B27 promotes inflammatory disease remains under active investigation. Current models converge on a common theme. HLA-B27 alters peptide handling and presentation, has an unusual tendency to misfold inside the endoplasmic reticulum, and can form alternative heavy-chain structures at the cell surface. These properties alter how innate and adaptive immune cells are engaged, potentially shifting the system toward chronic inflammation in susceptible hosts.

Three main mechanistic frameworks have emerged. Molecular mimicry focuses on cross-reactive recognition of microbial and self-peptides. Misfolding and endoplasmic reticulum stress emphasize the unfolded protein response and downstream cytokine cascades, particularly the IL-23 and IL-17 pathway. Heavy-chain homodimer models examine how non-classical HLA-B27 molecules on the cell surface signal through receptors on natural killer cells and other leukocytes. In addition, ongoing work examines the role of specific T-cell receptor repertoires and the possibility that HLA-B27 is tightly linked to other causal immune genes. Together, these mechanisms offer complementary explanations for how HLA-B27 changes immune signaling rather than a single, exclusive pathway.

Molecular Mimicry

Molecular mimicry proposes that peptides from infectious organisms resemble self-peptides presented by HLA-B27. A normal immune response to a microbial peptide can then cross-react with host tissues that display a similar peptide in the context of HLA-B27. In ankylosing spondylitis and related conditions, T-cell clones have been identified that recognize HLA-B27–presented microbial peptides and HLA-B27–presented self-peptides. These clones have been found in blood and synovial tissue in people with ankylosing spondylitis and acute anterior uveitis. Their presence supports the idea that a shared, antigen-driven mechanism can link joint and eye inflammation in HLA-B27–positive individuals.

Misfolding and Cellular Stress

The misfolding hypothesis highlights distinctive biochemical properties of HLA-B27 that make it prone to misfolding within the endoplasmic reticulum, where many proteins are processed and assembled. Accumulation of misfolded HLA-B27 can trigger an unfolded protein response, a stress pathway that helps cells manage misfolded proteins but also promotes inflammatory signaling when chronically activated. In this model, misfolded HLA-B27 triggers an unfolded protein response that increases interleukin-23 production. Elevated interleukin 23 then drives expansion and activation of T cells that produce interleukin 17. The IL-23-IL-17 axis plays a central role in many spondyloarthritides and in HLA-B27–associated uveitis, and has become an important therapeutic target in these conditions.

Heavy Chain Homodimers and Abnormal Signaling

A related proposal is the heavy chain homodimer hypothesis. In this model, HLA-B27 heavy chains form stable homodimers that accumulate within the endoplasmic reticulum and at the cell surface. These dimers may contribute to unfolded protein responses and can bind to specific receptors on natural killer cells and other leukocytes. Engagement of those receptors may promote survival and activation of pro-inflammatory cell populations. Experimental work supports a role for heavy-chain dimers in some settings, though other studies suggest they account for only part of the HLA-B27 effect, and they are considered one component of a broader mechanistic landscape.

Other Proposed Mechanisms

Additional lines of research suggest that susceptibility may involve particular T-cell receptor repertoires that recognize HLA-B27-bound peptides more readily, or that HLA-B27 may lie in tight linkage with another immune-response gene that has a more direct causal impact. The weight of current evidence indicates that no single mechanism fully accounts for disease risk. Instead, several HLA-B27–related pathways interact with non-HLA genetic factors and environmental exposures to produce the spondyloarthritis phenotype in a relatively small group of carriers.

Role of Infection and the Microbiome

The connection between HLA-B27 and conditions such as acute anterior uveitis and reactive arthritis appears to depend strongly on infection and the intestinal microbiome. Many cases of reactive arthritis and some uveitis flares follow gram-negative enteric or genitourinary infections involving organisms such as Shigella, Salmonella, Yersinia, Klebsiella, Ureaplasma, and Chlamydia. Components of these bacteria, including lipopolysaccharides, are highly immunogenic and can be presented by HLA-B27. In some individuals, chronic or recurrent infection of joints or ocular tissue with intracellular organisms, particularly chlamydiae, may sustain CD8 T-cell responses that injure synovium and ocular structures.

Beyond discrete infections, changes in the intestinal microbiome appear to modulate HLA-B27–associated risk. Microbial communities influence the set of peptides available for presentation, the tone of mucosal immune responses, and the threshold for systemic inflammation. Dysbiosis in HLA-B27 carriers can provide a steady source of stimuli that reinforce pathogenic T-cell responses and shape where and how inflammation emerges.

Gut–Joint–Eye Axis

Animal models offer strong support for a gut–joint–eye axis in HLA-B27–associated disease. Rodents engineered to express human HLA-B27 develop gut inflammation and arthritis when specific intestinal bacteria are present. Altering gut flora in these models changes the onset and severity of arthritis and related syndromes. In humans, both healthy HLA-B27 carriers and those with symptoms show differences in gut microbial communities compared with HLA-B27–negative individuals, and the degree of dysbiosis appears to correlate with symptom burden in some studies.

CD8 T-cell populations from HLA-B27–positive people can express gut-homing markers and are found in intestinal tissue and inflamed joints. These findings support a model in which T cells primed in the gut migrate to the eye and axial skeleton and contribute to disease. Taken together, experimental and clinical data suggest that HLA-B27 shapes immune responses in the intestine, that the intestinal environment, in turn, shapes T-cell populations, and that those cells can traffic to joints and ocular tissues, where they drive characteristic patterns of inflammation.

Current evidence supports a multifactorial model in which HLA-B27 alters peptide presentation, protein folding, cellular stress responses, and immune cell interactions. Environmental triggers, such as infections and shifts in the intestinal microbiome, then provide stimuli that initiate and sustain inflammation in the spine, peripheral joints, and the eye. This framework helps explain why only a fraction of HLA-B27–positive individuals ever develop spondyloarthritis or related conditions. It also underpins therapies targeting key inflammatory pathways, including the IL-23/IL-17 axis and tumor necrosis factor, with the goal of reducing symptoms, limiting structural damage, and preserving long-term function.

The IWBCA provides the information and materials on this site for educational and informational purposes only. The content is not a substitute for professional medical evaluation, diagnosis, or treatment. Always consult your physician or another qualified healthcare provider with any questions about a medical condition, diagnosis, or course of treatment. Do not disregard, delay, or alter medical advice based on information obtained from this site. If you believe you are experiencing a medical emergency, call 911 or your local emergency services immediately.